The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)
Permission is required for each single use of the MDS Clinical Outcome Assessments.
The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP) is a 4-question screening assessment for psychosis in PD, which can be self-administered or administered at patient intake. Development included input for patients, patient advocates, neurologists, and psychiatrists, following a modified Delphi plan, which included several rounds of revisions and Beta testing. The questionnaire shows very good sensitivity and specificity when compared to blinded interviews and administration of the Parkinson’s disease Psychosis Scale by PD experts. It is used only to assess the presence of psychosis and is not meant to be a severity scale.
Authors: Vindhya Koneru, Alberto J Espay, Allan J Cole, Daniel Weintraub, Kathleen Crist, Maria B Pascual, William G Ondo
Original Publication │ View the Scale (PDF) Permission required for use
- Acronym: SASPAP
- Year Published: 2023
- Scale Last Updated: No updates since publication
- Assessment Type: PROs
- Estimated Time to Complete: 2-4 minutes
Eletronic builds: REDCap
To request permission to use this Rating Scale, please fill out a Permission Request Form.
Inclusive Language in Clinical Outcome AssessmentsHealthcare providers should tailor the language used in COAs to reflect each patient’s gender identity. In grammatically gendered languages, the practice includes making appropriate linguistic adjustments to ensure communication is respectful and inclusive throughout the assessment process. |
